Myovant Sciences Ltd.
(NYSE : MYOV)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
0.65%91.281.3%$818.15m
AMGNAmgen Inc.
0.55%188.001.2%$644.03m
GILDGilead Sciences, Inc.
-0.08%66.710.9%$515.64m
BIIBBiogen Inc.
0.03%333.101.3%$451.66m
ILMNIllumina, Inc.
-1.07%299.043.5%$320.50m
REGNRegeneron Pharmaceuticals, Inc.
-0.47%418.612.6%$309.16m
VRTXVertex Pharmaceuticals Incorporated
0.27%187.371.9%$272.42m
ALXNAlexion Pharmaceuticals, Inc.
0.24%129.242.0%$236.10m
SRPTSarepta Therapeutics, Inc.
0.98%141.6315.4%$159.84m
AAgilent Technologies, Inc.
0.39%77.821.6%$142.95m
EXASExact Sciences Corporation
-1.68%84.1325.3%$128.44m
INCYIncyte Corporation
-0.50%83.662.5%$115.97m
ARRYArray BioPharma Inc.
0.58%23.238.2%$111.10m
EXELExelixis, Inc.
0.70%21.506.4%$85.11m
NBIXNeurocrine Biosciences, Inc.
0.33%81.165.1%$82.92m

Company Profile

Myovant Sciences, Inc. is a clinical-stage biopharmaceutical company. It focuses on developing and commercializing therapies for the treatment of women's health and endocrine diseases. The company's product includes relugolix, which is an oral, once-daily and small molecule that acts as a GnRH receptor antagonist. It also develops MVT-602 a kisspeptin agonist for the treatment of female infertility. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.